Camrelizumab + chemotherapy+Thalidomide
MA-NSCLC-II-039
Approved small_molecule active
Quick answer
Camrelizumab + chemotherapy+Thalidomide for Lung Cancer is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Lung Cancer
- Phase
- Approved
- Modality
- small_molecule
- Status
- active